7. Control of allergic airway inflammation through immunomodulation - 15/08/11
Houston, TexThis activity is available for CME credit. See page 5A for important information.
Abstract |
Among the asthma clinical trials published over the last several years, a unique subset has focused on novel means for inhibiting the airway inflammation that is believed to cause airway obstruction in many patients. Such interventions, broadly considered here as immune-modifying or immunomodulatory therapies, include several new drugs (omalizumab, suplatast tosilate, anti-cytokine antibodies, soluble receptors, and recombinant cytokines) and bacterial extracts. In this chapter we review the major findings with these clinical trials and indicate which have changed the management of asthma, which have not, and those that deserve further study.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, IgE, type I hypersensitivity, immunomodulation, TH2 cell, eosinophil, mast cell, interleukin, airway hyperreactivity, immunostimulatory sequence
Abbreviation used : sIL-4R⍺
Plan
Supported by National Institutes of Health grants HL69585 and HL75243 (to D.B.C.) and HL64061 and HL72062 (to F.K.). |
Vol 117 - N° 2S2
P. S461-S464 - février 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?